

Annex 3 - Country-level monitoring indicators for polio transition plan implementation, reported and monitored on yearly basis

Objective 1: Sustaining a polio-free world after eradication

Output indicators	1.1. Coverage with inactivated polio vaccine		1.2. High-quality surveillance for acute flaccid paralysis				1.3. Polio outbreak & Endemic						1.4. High-quality environmental surveillance for poliovirus			
Country level monitoring	1.1.1. IPV1 Coverage	1.1.2. Coverage with bivalent OPV (POL3)	1.2.1. Rate of non-polio AFP		1.2.2. % of AFP cases with adequate stool specimens		1.3.1. Number of cases		1.3.2. Type of poliovirus		1.3.3. Year End Active Outbreak (Virus within 6m)		1.4.1. Number of environmental surveillance sites		1.4.2. Average number of samples per site	
Years	2019	2019	2019	2020	2019	2020	2019	2020	2019	2020	2019	2020	2019	2020	2019	2020
Afghanistan	66%	73%	23.9	22.9	94%	93%	29	274; 56	WPV1	cVDPV2; WPV1		3	21	23	12	18
Angola	43%	51%	3.5	3.6	82%	82%	114	3	cVDPV2	cVDPV2	6†	0	9	9	12	11
Bangladesh	92%	98%	3.1	2.2	100%	100%							8	8	18	17
Cameroon	67%	68%	5.7	7.1	83%	82%	^	7	cVDPV2 (ES)	cVDPV2		2	34	28	18	10
Chad	49%	47%	11.0	14.3	89%	87%	3	98	cVDPV2	cVDPV2	1	3	5	5	39	15
DR Congo	60%	59%	8.9	7.9	86%	88%	84	75	cVDPV2	cVDPV2	5	2	14	18	21	9
Ethiopia	68%	72%	2.8	3.1	91%	90%	11	21	cVDPV2	cVDPV2	2	3	6	3	27	17
India	82%	90%	11.0	5.7	87%	82%							53	50	34	22
Indonesia	76%	85%	2.4	0.6	81%	82%	‡		cVDPV1				33	19	5	4
Iraq	93%	85%	7.1	3.8	94%	94%										
Libya	74%	73%	5.9	4.5	98%	100%										
Myanmar	90%	90%	3.0	1.5	90%	90%	6		cVDPV1		1		3	4	24	8
Nepal	80%	92%	3.9	2.1	98%	97%							5	5	24	10
Nigeria	53%	57%	8.5	8.7	94%	95%	18	8	cVDPV2	cVDPV2	4	3	126	159	17	8
Pakistan	75%	75%	21.2	19.3	87%	87%	144(22)	135;84	WPV1 & (cVDPV2)	cVDPV2; WPV1	5†	9	72	72	12	11
Somalia	42%	47%	5.0	7.8	96%	95%	3	14	cVDPV2	cVDPV2	1	1	4	5	23	9
South Sudan	39%	50%	7.1	7.1	90%	86%		38		cVDPV2		1	5	5	22	17
Sudan	91%	93%	3.6	4.1	96%	93%		56		cVDPV2		2	5	17	13	5
Syrian Arab Republic	71%	60%	5.8	4.5	88%	91%							15		12	12
Yemen	68%	67%	6.7	6.7	89%	89%		28		cVDPV2		1				

^ES positive

‡Other Human Specimens tested positive

ES numbers fluctuate as sites open and close; samples per site by region/global is not possible as not all results are provided from all sites

Objective 2: Strengthen immunization systems and surveillance
Objective 3: Strengthen emergency preparedness, detection and response

Output indicators	2.1. Vaccine coverage with one and two doses of measles containing vaccine			2.2. Government expenditure on routine immunization in US\$ per newborn	3. Countries prepared for health emergencies		
Country level monitoring	2.1.1. MCV1 coverage	2.1.2. MCV2 coverage	2.1.3. % of districts with MCV2 >80%		3.1. Average % of IHR self-assessment annual reporting of laboratory core capacity	3.2. Average % of IHR self-assessment annual reporting of surveillance core capacity	3.3. Average % of IHR self-assessment annual reporting of emergency framework core capacity
Years	2019	2019	2019	2019	2020	2020	2020
Afghanistan	64%	39	0	3.7 (2018)	60%	70%	80%
Angola	51%	45	22	26.6	67%	100%	73%
Bangladesh	97%	95	98	13.4	73%	80%	53%
Cameroon	60%	-	-	10.8	60%	80%	53%
Chad	41%	-	-	3.5	60%	80%	33%
DR Congo	57%	-	-	2.1	60%	60%	60%
Ethiopia	58%	41	31	9.2	80%	80%	87%
India	95%	84	56	12.1	73%	100%	80%
Indonesia	88%	71	30	19.1	100%	80%	80%
Iraq	82%	86	73	-	73%	70%	87%
Libya	73%	72	100	-	73%	80%	33%
Myanmar	84%	80	65	16.6	73%	90%	47%
Nepal	92%	76	34	9.5	53%	50%	47%
Nigeria	54%	9	1	3.6 (2018)	60%	80%	60%
Pakistan	75%	71	36	16.2	60%	60%	60%
Somalia	46%	-	-	-	-	-	-
South Sudan	49%	-	-	1.2 (2017)	60%	80%	40%
Sudan	90%	74	45	5.8	60%	80%	60%
Syrian Arab Republic	59%	54	57	17.2	47%	60%	53%
Yemen	67%	46	7	-	67%	80%	60%

Sources: GPEI, WHO, WHO-UNICEF Joint Reporting Form, United Nations, Department of Economic and Social Affairs, Population Division (2019). World Population Prospects: The 2019 Revision; WHO Global Health Observatory, International Health Regulation, IHR States Parties Score per capacity (2019)